Asset Details
Do you wish to reserve the book?
Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer
Do you wish to request the book?
Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer
2005
Overview
776.1 is a murine IgG1 monoclonal antibody to the human ovarian cancer antigen CA 125 that has the unique property of having a clear preference for binding to the cell-associated form of the antigen. We have examined the tumor localization properties and efficacy of 776.1 in a subcutaneous OVCAR-3 xenograft mouse model of human ovarian cancer. Biodistribution experiments using 125I-labeled 776.1 demonstrated a peak uptake in tumors at 72 hours postinjection, with an average of 17.7% of injected dose per gram localized to the tumor. Little uptake in other organs was observed. Further experiments using CA 125-transfected syngeneic tumors, as well as an immunoprecipitation assay using human chimeric 776.1, both clearly demonstrated that 776.1 localizes to the tumor in a CA 125-dependent manner. DOTA-776.1 (1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″ tetraacetic acid-conjugated 776.1) was labeled with 90Y and used in efficacy studies. [90Y-DOTA]776.1 at a single dose of 150 µCi was able to mediate efficient reduction of tumor growth, with regression observed in a subset of animals for a period ranging from 3 to 48 days, equivalent to 3 weekly administrations of cisplatin at 6 mg/kg. No significant regression was observed in groups receiving [90Y-DOTA]MOPC-21 control antibody at any dose. These results suggest that 776.1 may be a promising radioimmunotherapeutic agent for the treatment of human ovarian cancer.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
Subject
/ Antibodies, Monoclonal - pharmacokinetics
/ Antibodies, Monoclonal - therapeutic use
/ Female
/ Humans
/ Immunoglobulin G - metabolism
/ Immunoglobulin G - therapeutic use
/ Iodine Radioisotopes - pharmacokinetics
/ Iodine Radioisotopes - therapeutic use
/ Mice
/ Ovarian Neoplasms - radiotherapy
/ Radioimmunotherapy - methods
/ Transplantation, Heterologous
